Protein Summary
Multifunctional adapter protein involved in diverse array of functions including trafficking of transmembrane proteins, neuro and immunomodulation, exosome biogenesis, and tumorigenesis (PubMed:26291527). Positively regulates TGFB1-mediated SMAD2/3 activation and TGFB1-induced epithelial-to-mesenchymal transition (EMT) and cell migration in various cell types. May increase TGFB1 signaling by enhancing cell-surface expression of TGFR1 by preventing the interaction between TGFR1 and CAV1 and subsequent CAV1-dependent internalization and degradation of TGFR1 (PubMed:25893292). In concert with SDC1/4 and PDCD6IP, regulates exosome biogenesis (PubMed:22660413). Regulates migration, growth, proliferation, and cell cycle progression in a variety of cancer types (PubMed:26539120). In adherens junctions may function to couple syndecans to cytoskeletal proteins or signaling components. Seems to couple transcription factor SOX4 to the IL-5 receptor (IL5RA) (PubMed:11498591). May also play a role ...more
- ENST00000260130
- ENSP00000260130
- ENSG00000137575
- ENST00000413219
- ENSP00000411771
- ENST00000424270
- ENSP00000395351
- ENST00000447182
- ENSP00000409288
- MDA9
- SYCL
- ST1
- MDA9
- SYCL
- MDA-9
- TACIP18
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 1 | ||
transcription factor perturbation | 0.97 | ||
virus perturbation | 0.94 | ||
cellular component | 0.92 | ||
molecular function | 0.86 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 647.64 (req: < 5)
Gene RIFs: 73 (req: <= 3)
Antibodies: 463 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 647.64 (req: >= 5)
Gene RIFs: 73 (req: > 3)
Antibodies: 463 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 28
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 7
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0